|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 12:33am | GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment | MT |
| 09:45pm | GSK : DZ Bank remains Neutral | ZD |
| Market Cap | 80.42B 107B 93.88B 87.63B 151B 10,233B 154B 1,039B 406B 5,064B 401B 392B 17,506B | P/E 2026 * |
12.8x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 102B 135B 119B 111B 191B 12,966B 195B 1,317B 515B 6,416B 508B 497B 22,181B | EV / Sales 2026 * |
3x | EV / Sales 2027 * | 2.62x |
| Free-Float |
93.18% | Yield 2026 * |
3.47% | Yield 2027 * | 3.64% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | +2.94% | +49.73% | +163.92% | 1,089B | |
| -0.45% | +5.95% | +59.75% | +52.18% | 643B | |
| +0.04% | +2.81% | +39.67% | +74.54% | 465B | |
| -1.69% | +8.36% | +38.80% | +34.26% | 359B | |
| -0.51% | +3.35% | +39.00% | +43.76% | 303B | |
| +1.50% | +5.14% | +21.72% | +18.77% | 267B | |
| +0.79% | +4.32% | -25.07% | -36.02% | 226B | |
| -1.39% | +5.84% | +28.66% | +64.00% | 212B | |
| -1.18% | +1.88% | +17.43% | +72.69% | 167B | |
| Average | -0.32% | +4.30% | +29.96% | +54.23% | 414.57B | |
| Weighted average by Cap. | -0.39% | +4.43% | +39.10% | +79.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.97B 45.13B 39.65B 37.01B 63.59B 4,322B 65.15B 439B 172B 2,139B 169B 166B 7,394B | 35.64B 47.35B 41.61B 38.84B 66.72B 4,536B 68.37B 461B 180B 2,244B 178B 174B 7,759B |
| Net income | 6.39B 8.49B 7.46B 6.96B 11.96B 813B 12.26B 82.58B 32.29B 402B 31.88B 31.18B 1,391B | 6.95B 9.24B 8.12B 7.58B 13.02B 885B 13.34B 89.86B 35.14B 438B 34.69B 33.94B 1,514B |
| Net Debt | 21.48B 28.53B 25.07B 23.4B 40.21B 2,733B 41.2B 278B 109B 1,352B 107B 105B 4,675B | 12.91B 17.15B 15.07B 14.06B 24.16B 1,642B 24.75B 167B 65.21B 813B 64.37B 62.97B 2,809B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
